Noropsikiyatri Arsivi-Archives of Neuropsychiatry最新文献

{"title":"Clinical Characteristics and Treatment Resistance of Trigeminal Neuralgia in Multiple Sclerosis Patients: A Retrospective Observational Study.","authors":"Mehmet İlker Yön, Ersin Kasım Ulusoy","doi":"10.29399/npa.29088","DOIUrl":"10.29399/npa.29088","url":null,"abstract":"<p><strong>Introduction: </strong>Trigeminal neuralgia (TN) is a neuropathic pain syndrome characterized by sudden, severe, and short-lived pain attacks in the facial region. When TN is associated with multiple sclerosis (MS), it may present distinct clinical features. The frequency of refractory TN and treatment responses in MS patients remain controversial in the literature. This study aims to investigate the clinical characteristics of MS-associated TN and assess whether TN is more treatment-resistant in MS patients.</p><p><strong>Methods: </strong>This retrospective observational study analyzed the clinical and demographic data of patients diagnosed with TN and MS who presented to the Neurology Outpatient Clinic of Ankara Bilkent City Hospital between 2019 and 2025. The study included 36 MS patients with TN and 36 TN patients without MS, matched for age and sex. Variables such as age, sex, disease duration, MS type, Expanded Disability Status Scale (EDSS) score, TN onset age, TN treatment history, and magnetic resonance (MR) imaging findings were recorded. Refractory TN was defined as TN that did not respond to first- and second-line pharmacological treatments and required interventional procedures.</p><p><strong>Results: </strong>The mean age of MS patients with TN was 51.19±10.78, similar to that of non-MS TN patients (p=0.97). While no significant differences were found in TN clinical characteristics between groups, MRI revealed a higher frequency of TN-associated brainstem lesions in MS patients (p=0.04). The rates of local anesthetic ganglion block and radiofrequency ablation were significantly higher in MS patients (p=0.01, p=0.02). Barrow Neurological Institute Pain Scale (BNI-PS) scores were significantly higher in MS patients (p=0.001), and the prevalence of refractory TN was markedly greater in the MS group (p=0.01). A positive correlation was observed between refractory TN and EDSS scores in MS patients (p=0.002, r=0.482).</p><p><strong>Conclusion: </strong>This study demonstrates that TN is more resistant to treatment in MS patients, with a higher prevalence of refractory TN. Furthermore, the increased pain severity and greater need for interventional treatments in MS patients suggest that alternative management strategies are required for MS-associated TN. Larger-scale prospective studies are needed to evaluate treatment responses and long-term outcomes in this population.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"108-111"},"PeriodicalIF":1.1,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-Esteem and Symptom Severity in General Anxiety Disorder and Major Depressive Disorder: A Serial Mediation Model of Experiential Avoidance and Psychological Resilience.","authors":"Ayse Erguner Aral, Gizem Gerdan, Armagan Aral, Esin Erdogan","doi":"10.29399/npa.29094","DOIUrl":"10.29399/npa.29094","url":null,"abstract":"<p><strong>Introduction: </strong>Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) are prevalent mental health conditions, and low self-esteem is considered a vulnerability factor for psychological distress. However, the relationship between self-esteem and symptom severity remains unclear, as evidence regarding the nature of this association is still insufficient. On the other hand, experiential avoidance is recognized as a transdiagnostic variable closely linked to clinical outcomes and individual characteristics, while also being associated with psychological resilience. This study investigates the serial mediating roles of experiential avoidance and psychological resilience in the relationship between self-esteem and the severity of anxiety and depressive symptoms in individuals diagnosed with GAD and MDD.</p><p><strong>Methods: </strong>The study was conducted with 201 voluntary participants aged between 18 and 65 who had been diagnosed with either GAD (n = 90) or MDD (n = 111) and were being monitored accordingly. Participants were assessed using a sociodemographic and clinical data form prepared by the interviewer, along with the Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Psychological Resilience Scale, Rosenberg Self-Esteem Scale, and the Multidimensional Experiential Avoidance Questionnaire.</p><p><strong>Results: </strong>The results indicate an indirect relationship between self-esteem and anxiety and depressive symptoms, mediated by experiential avoidance and psychological resilience. This mediation effect was found to be complete for anxiety and partial for depression. Sensitivity analysis confirmed the robustness of the mediation findings.</p><p><strong>Conclusion: </strong>The findings suggest that individuals diagnosed with GAD and MDD tend to adopt more experiential avoidance strategies in relation to low self-esteem, which in turn leads to a decrease in psychological resilience and an increase in symptom severity. Accordingly, interventions targeting experiential avoidance in the context of self-esteem may contribute to symptom reduction by enhancing psychological resilience.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"112-118"},"PeriodicalIF":1.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Combined Peripheral Nerve Blocks Versus Isolated Greater Occipital Nerve Block in the Management of Cluster Headache.","authors":"Mehmet İlker Yön, Ersin Kasım Ulusoy, Burçak Baraz, Tahir Kurtuluş Yoldaş","doi":"10.29399/npa.29145","DOIUrl":"10.29399/npa.29145","url":null,"abstract":"<p><strong>Introduction: </strong>Cluster headache (CH) is a primary headache disorder classified under trigeminal autonomic cephalalgias, characterized by severe, disabling pain attacks. In treatment-resistant cases, where pharmacological interventions are insufficient, peripheral nerve blocks have emerged as a promising interventional option. This study aimed to compare the efficacy of isolated greater occipital nerve (GON) block with combined GON, supraorbital nerve (SON), and sphenopalatine ganglion (SPG) blocks in reducing attack frequency, pain intensity, and treatment response in patients with CH.</p><p><strong>Methods: </strong>This retrospective study included 44 patients diagnosed with CH according to the The International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria, who were treated at Ankara Bilkent City Hospital Neurology Clinics between August 2021 and December 2024.</p><p><strong>Patients were divided into two groups: </strong>those who received GON block alone (n=18) and those who underwent combined GON+SON+SPG blocks (n=26). Demographic and clinical data were collected. Attack frequency, pain duration, and Barrow Neurological Institute Pain Scale (BNI-PS) scores were evaluated at baseline, and at the 1st week and 1st month following intervention.</p><p><strong>Results: </strong>Compared to the GON-only group, patients in the combined block group showed significantly greater reductions in both attack frequency and BNI-PS scores at both follow-up points (p<0.05). Moreover, the duration of pain resolution was significantly shorter in the combined block group (8.96 ± 6.13 days vs. 18.28 ± 17.89 days; p=0.046). No significant differences were found between the groups in terms of baseline demographic or other clinical variables.</p><p><strong>Conclusion: </strong>Our findings suggest that combined peripheral nerve blocks involving the GON, SON, and SPG are more effective than GON block alone in reducing attack burden and pain duration in patients with CH. This interventional approach may offer a valuable alternative for patients who are unresponsive to conventional medical therapies.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"258-262"},"PeriodicalIF":1.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Impact of COVID-19 on Cognitive Functions Through Event-Related Potentials Analysis.","authors":"Erdal Eroğlu, Javid Shafiyev, Akçay Övünç Karadaş, Ömer Karadaş","doi":"10.29399/npa.29152","DOIUrl":"10.29399/npa.29152","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 infection affects many systems, particularly the central nervous system. These effects are observed at different levels across various age groups. Although there are studies in the literature examining the negative effects of COVID-19 infection on cognitive functions, research including neurophysiological tests supporting these effects is limited. The aim of this study is to demonstrate the effect of COVID-19 infection on cognitive functions according to age through neurophysiological parameters.</p><p><strong>Methods: </strong>This prospective study was conducted at the COVID-19 clinic from June 2020 to June 2021. Inclusion criteria comprised PCR-confirmed mild to moderate COVID-19 patients aged under 50 and over 65, as well as a PCR-negative control group comprised of individuals aged under 50 and over 65. Exclusion criteria included individuals under 18 years old, and participants from both the patient and control groups were selected without conditions such as dementia that could influence cognitive functions, as well as severe clinical presentations of COVID-19. In hospitalized patients, N200/P300 latencies and N2P3 amplitudes were measured on the first day of admission and again on the 60th day post-discharge for those with positive COVID-19 PCR tests. For PCR-negative patients, measurements were taken only once on the first day of admission.</p><p><strong>Results: </strong>The study encompassed a cohort of 48 COVID-19 PCR-positive patients alongside 47 PCR-negative subjects (constituting the control group). Statistically significant differences were observed between the COVID-19 PCR-positive and negative groups (p<0.05). Additionally, significant differences in event-related potentials were found between the PCR-positive groups aged under 50 and those over 65 years (p<0.05). After discharge, significant improvement was observed on the 60th day in the group under 50 years of age (p<0.05), while no statistically significant improvement was detected in the group over 65 years (p>0.05).</p><p><strong>Conclusion: </strong>Our study demonstrated that COVID-19 has a negative impact on cognitive functions, which becomes more pronounced with advancing age.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"263-269"},"PeriodicalIF":1.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tonsillar Alpha-Synuclein Accumulation on Parkinson's Disease.","authors":"Cansu Sarıkaya, Sebla Çalışkan, Özkan Özdemir, Mete İşeri, Pervin İşeri","doi":"10.29399/npa.29107","DOIUrl":"10.29399/npa.29107","url":null,"abstract":"<p><strong>Introduction: </strong>Parkinson's disease (PD) is a neurodegenerative disorder caused by the misfolding of alpha-synuclein (α-synuclein) proteins. Despite treatment, misdiagnosis rates can reach up to 50% within the first five years, highlighting the need for reliable biomarkers. However, the presence and role of α-synuclein in lymphatic tissues, such as the tonsils, have not been adequately investigated. The tonsils are accessible lymphatic organs that may serve as potential sites for α-synuclein accumulation due to their rich innervation and immune activity. Therefore, this study aims to investigate and compare α-synuclein levels in the tonsillar tissues of patients with Parkinson's disease and healthy controls. By evaluating the tonsils as a potential site of α-synuclein deposition, this study aims to explore their role as a possible biomarker.</p><p><strong>Methods: </strong>After ethical approval, participants were selected from Neurology Outpatient Clinic diagnosed with idiopathic Parkinson's per UK Parkinson's Disease Society Brain Bank Criteria. The control group comprised individuals undergoing tonsillectomy with no neurological symptoms. We collected and analyzed tonsil tissues from 15 control and 11 PD patients using ELISA to determine α-synuclein concentrations. Data were analyzed using IBM SPSS 25.0, employing Mann-Whitney U and Kolmogorov-Smirnov tests to evaluate differences in α-synuclein levels, with significance set at p<0.05.</p><p><strong>Results: </strong>No significant age or gender differences were noted between groups. PD patients showed higher α-synuclein concentrations in tonsillar tissues compared to controls, with statistical significance.</p><p><strong>Discussion: </strong>Our results suggest that tonsillar tissue could serve as a novel peripheral biomarker, potentially reflecting α-synuclein accumulation in PD. Future studies are needed to clarify the underlying mechanism of α-synuclein deposition in tonsils, its correlation with disease severity and progression and its potential role in monitoring treatment response.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"232-234"},"PeriodicalIF":1.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Head Awareness in Patients with Chronic Migraine Using the Fremantle Headache Awareness Questionnaire: Turkish Version, Validity, and Reliability Study.","authors":"Dilara Onan, Halime Arıkan, Doğa Vurallı, Merve Ceren Akgör, Ayşenur Başel Pala, Ece Yanık, Ayşe İrem Can, Can Ulutaş, Pelin Yenilmez Yeşildaş, İrem Yıldırım, Pınar Gelener, Esra Acıman Demirel, Esme Ekizoğlu, Aynur Özge","doi":"10.29399/npa.29190","DOIUrl":"10.29399/npa.29190","url":null,"abstract":"<p><strong>Introduction: </strong>In chronic migraine (CM), patient-reported outcome measures (PROMs) are important, as headaches may be related to impaired proprioception and somatic bodily awareness in the chronicity. This study aimed to adapt the Fremantle Headache Awareness Questionnaire (FreHAQ) to Turkish.</p><p><strong>Methods: </strong>Patients aged 18-70 were included in the study. After cross-cultural adaptation of the questionnaire, demographic-clinical information was recorded. Numeric Pain Rating Scale (NPRS), Migraine Disability Assessment (MIDAS), Headache Impact Test-6 (HIT-6), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS) and FreHAQ were evaluated for structural validity. Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) were also performed. Intraclass Correlation Coefficient (ICC) and Cronbach's α values were calculated for reliability.</p><p><strong>Results: </strong>A total of 180 patients (mean age was 39.94±13.14 years) were included. Headache attacks occurred 17.12±4.53days/month, with 7.57±2.1 intensity. Item-total correlations ranged from 0.079 to 0.673. Cronbach's α value was above 0.811. FreHAQ had good test-retest reliability (ICC=0.851, n=73) and high internal consistency (Cronbach's α=0.919). The absence of a significant difference between baseline and retest scores (p=0.06) supported the temporal stability of FreHAQ. FreHAQ correlated with NPRS, MIDAS, HIT-6, HADS, and PCS (p<0.01). EFA identified a two-factor structure, explaining 56.98% of the variance (proprioceptive-motor awareness (items 1-6,9) and shape-size awareness of the head (items 7,8)). CFA showed acceptable model fit.</p><p><strong>Conclusion: </strong>The Turkish version of FreHAQ is a valid and reliable tool to assess perceptual impairments in CM and is significantly associated with psychosocial factors. Monitoring body awareness in chronic headache can be important for PROMs.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"308-315"},"PeriodicalIF":1.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of Serum Humanin-Like 3 Levels in Multiple Sclerosis Patients with Predominant Optic Nerve and Spinal Cord Involvement: A Preliminary Study.","authors":"Cem İsmail Küçükali, Nuray Sancar, Hande Yüceer Korkmaz, Tuncay Gündüz, Murat Kürtüncü, Erdem Tüzün","doi":"10.29399/npa.29115","DOIUrl":"10.29399/npa.29115","url":null,"abstract":"<p><strong>Introduction: </strong>Our aim was to determine whether serum levels of humanin-like 3 (encoded by the MTRNR2L3 gene) may serve as a diagnostic biomarker for differentiation of NMOSD from relapsing remitting multiple sclerosis (RRMS) presenting with clinical features reminiscent of NMOSD.</p><p><strong>Methods: </strong>Humanin-like 3 levels were measured by ELISA in sera of 30 RRMS patients, 10 NMOSD patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON) and 23 healthy controls.</p><p><strong>Results: </strong>MS-SCON patients showed significantly higher humanin-like 3 levels than other groups. Receiver operating characteristic (ROC) curve analysis showed that 5.26 ng/ml cut-off value of humanin-like 3 level discriminated MS-SCON from NMOSD by 66.7% sensitivity and 90% specificity. Humanin-like 3 levels did not correlate with demographic and clinical variables of MS and NMOSD.</p><p><strong>Conclusion: </strong>Serum humanin-like 3 level might potentially be used as a biomarker in differential diagnosis of MS patients presenting with NMOSD-like features. Elevated humanin-like 3 levels of MS-SCON patients might be an indicator of increased stress on neuronal survival in this MS subgroup.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"242-245"},"PeriodicalIF":1.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks.","authors":"Duygu Özkan Yaşargün, Ayça Simay Ersöz, Recai Türkoğlu, Erdem Tüzün","doi":"10.29399/npa.28978","DOIUrl":"10.29399/npa.28978","url":null,"abstract":"<p><strong>Introduction: </strong>Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating autoimmune condition that, without timely intervention, can lead to severe disability or even death. Neuromyelitis optica spectrum disorder is an inflammatory disease of the central nervous system characterized by severe attacks such as optic neuritis and transverse myelitis. This study compared the short- and long-term effects of high-dose intravenous methylprednisolone (IVMP) and IVMP+plasma exchange (PLEX) treatment regimens.</p><p><strong>Methods: </strong>The study evaluated changes in patients' Expanded Disability Status Scale (EDSS) scores over a six-month follow-up period by using different ANOVA and linear regression methods.</p><p><strong>Results: </strong>Both IVMP and IVMP+PLEX treatments resulted in clinical improvement, with the addition of PLEX showing a more significant reduction in EDSS scores, particularly during the long follow-up period. Moreover, seropositive patients (AQP4/MOG-IgG positive) demonstrated a better response to treatment. Age and baseline EDSS scores were identified as key factors influencing post-treatment improvement.</p><p><strong>Conclusion: </strong>Our results suggest that the addition of PLEX to IVMP treatment might be suitable especially for severe NMOSD attacks.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"62 4","pages":"354-359"},"PeriodicalIF":1.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12694813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body-Focused Repetitive Behaviors in Adolescents and Young Adults: Co-Occurrence Patterns, Psychiatric Comorbidities and Turkish Validity and Reliability Study of the Generic Body-Focused Repetitive Behavior Scale-8.","authors":"Hande Günal Okumuş, Makbule Esen Öksüzoğlu, hMeryem Kaşak, Doğancan Sönmez, Burak Okumuş, Ayşe Selma Yenen Menderes, Nazlı Merve Korkmaz, İsranur Yenen Sivri, Yusuf Selman Çelik, İrem Kar, Steffen Morıtz","doi":"10.29399/npa.29099","DOIUrl":"10.29399/npa.29099","url":null,"abstract":"<p><strong>Introduction: </strong>Body-focused repetitive behaviors (BFRBs) are common but often underdiagnosed and undertreated, with limited understanding of their development. The eight-item Generic Body-Focused Repetitive Behavior Scale-8 (GBS-8) provides a practical, transdiagnostic self-report instrument. The aim of this study was to evaluate the reliability and validity of the Turkish GBS-8 and to examine patterns of BFRBs in a clinical sample of adolescents and young adults.</p><p><strong>Method: </strong>The sample included 362 adolescents and young adults aged 12-30 years with at least one subclinical or pathological BFRB. Adolescents completed the GBS-8, the Brief Symptom Inventory (BSI), and the Pediatric Quality of Life Inventory (PedsQL), while young adults completed the GBS-8, the BSI, and the Short Form-12 Health Survey (SF-12). Researchers completed the Clinical Global Impression-Severity subscale (CGI-S) to assess the severity of BFRBs.</p><p><strong>Results: </strong>Participants had a mean age of 17.74 ± 5.04 years, with 78.7% identifying as female. The Turkish GBS-8 showed strong internal consistency and a well-fitting two-factor structure, including symptom severity (α = 0.853), impairment (α=0.779), and the total score (α=0.855). The test-retest reliability analysis further supported the scale's validity and reliability, with a Cronbach's alpha coefficient of 0.851. A total of 50 different BFRB patterns were identified, the most common of which were skin picking, nail biting, lip/cheek biting, and knuckle cracking (8.56%), followed by only nail biting (8.01%) and a combination of nail biting, lip/cheek biting and knuckle cracking (7.18%).</p><p><strong>Conclusion: </strong>The findings confirm the Turkish validity and reliability of the GBS-8, supporting its utility in clinical settings. This study also highlights the need for increased awareness and tailored interventions to improve BFRBs management.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"119-128"},"PeriodicalIF":1.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum High Mobility Group Box Protein-1 Levels in Schizophrenia During Acute Psychotic Episodes and Remission.","authors":"Seda Tanrıverdi Oluğ, Özlem Devrim Balaban, Aysu Kara","doi":"10.29399/npa.29013","DOIUrl":"10.29399/npa.29013","url":null,"abstract":"<p><strong>Objective: </strong>High mobility group box-1 (HMGB1) is a non-histone protein that plays a role in neuroinflammation by inducing cytokines. We aimed to compare HMGB1 levels in patients with schizophrenia in both acute exacerbation and remission phases and in healthy controls and to determine whether HMGB1 correlates with symptom severity and C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR).</p><p><strong>Methods: </strong>The study included 31 schizophrenia patients in remission and 31 schizophrenia patients hospitalised for acute psychotic exacerbation and 30 healthy controls. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay (ELISA). Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Scale (CGI) were used to assess symptom severity.</p><p><strong>Results: </strong>Serum HMGB1 levels were found to be significantly higher in both the remission group (140.48±63.52 pg/ml) and the acute exacerbation group (125.92±48.71 pg/ml) compared to healthy controls (57.44±13.04 pg/ml) (p<0.05). There was no statistically significant difference in serum HMGB1 levels between patients in remission and patients in acute psychotic exacerbation. There was no correlation between serum HMGB1 levels and severity of symptoms. No significant correlation was found between serum HMGB1 levels and other inflammatory markers. There was a statistically significant negative correlation between serum HMGB1 levels and chlorpromazine-equivalent antipsychotic doses (rs=-0.316, p=0.047).</p><p><strong>Conclusions: </strong>Our findings suggest that HMGB1 levels are elevated in individuals with schizophrenia, regardless of phase, which may reflect trait-like characteristics of the disorder. However, further research is needed to confirm this. Increased HMGB1 may contribute to schizophrenia pathogenesis through neuroinflammation.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"41-48"},"PeriodicalIF":1.1,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}